Exosomal protein CD82, gpc1 combined with ca19-9 for early diagnosis and curative effect monitoring of pancreatic cancer
An exosome, pancreatic cancer technology, applied in the field of medical biological detection, can solve the problem of not fully representing the condition of pancreatic cancer
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0191] Embodiment 1: preparation kit of the present invention
[0192] The kit of the present invention consists of the following:
[0193] A) CA19-9 assay contains reagents
[0194] 1) R1: Access CA19-9 kit (Access CA19-9 kit was purchased from Beckman (Access® GIMonitor - 2 packs of 50 tests / pack Cat#387687)): 50 tests / box;
[0195] 2) R1a: magnetic particles coated with biotin-labeled goat anti-CA19-9 monoclonal antibody;
[0196] 3) R1b: Goat anti-CA19-9 monoclonal antibody labeled with alkaline phosphatase;
[0197] 4) R2: Neutral detergent.
[0198] 5) S1~S6: Access CA19-9 calibrators include S1, S2, S3, S4, S5, S6:, the concentrations of CA19-9 contained in them are 0, 30, 90, 300, 900, 2000U / ml respectively .
[0199] B) Detection reagents for GPC1 and CD82 protein expression in exosomes:
[0200] 1) Exosome isolation: Density gradient medium-1 (Density gradient medium-1) 6ml
[0201] 2) Density gradient medium-2 (Density gradient medium-2) 6ml
[0202] 3) Dens...
Embodiment 2
[0219] Embodiment 2: the detection method of the kit of embodiment 1
[0220] 1. Blood sample collection and sample preparation:
[0221] Due to the advantages of convenient, non-invasive, and continuous detection of peripheral blood, the use of peripheral blood to detect pancreatic cancer diagnostic biomarkers can detect the occurrence of pancreatic cancer early, and improve the early clinical diagnosis of pancreatic cancer to a new level.
[0222]Blood samples were collected from Datong Tongmei Hospital in Shanxi, Hebei Provincial People's Hospital, and Shanghai Sixth People's Hospital: 24 healthy volunteers and 26 pancreatic cancer patients. Sample collection: Collect about 3-6 ml of peripheral blood from the patient and put it into a vacuum coagulation tube, invert it several times to fully combine, let it stand for about half an hour, centrifuge at 1600g for 10 minutes, and transfer the supernatant to a new tube. The supernatant was centrifuged at 12000 g for 10 min for ...
Embodiment 3
[0266] Example 3: Logistic regression analysis and ROC curve analysis of peripheral blood CA19-9 content, Exo-CD82+ and Exo-GPC1+ expression in healthy people and pancreatic cancer patients
[0267]The present invention detected the content of CA19-9 and the expression levels of Exo-GPC1+ and Exo-CD82+ in the serum of 26 healthy people and 24 patients with pancreatic cancer. Through logistic regression and ROC curve analysis, it was found that CA19-9, Exo-GPC1+ and Exo- CD82+ combined diagnosis of pancreatic cancer has the most significant AUC 联合诊断 =0.942, P CA19-9 =0.7340, P GPC1 =0.8846, P CD82 =0.8518, P <0.01) were also superior to CA19-9 diagnosis alone (Table 2).
[0268] Table 2 ROC analysis of combined diagnosis of peripheral blood CA19-9, Exo-CD82+ and Exo-GPC1+ in healthy people and pancreatic cancer patients
[0269]
PUM
Property | Measurement | Unit |
---|---|---|
coupling rate | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com